Loading clinical trials...
Loading clinical trials...
A Retrospective Study of Clinical Outcomes in Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients Treated With Daratumumab, Lenalidomide and Dexamethasone (DRd) Outside of Clinical Trials in the UK
Conditions
Locations
1
United Kingdom
The Royal Wolverhampton NHS Trust
Wolverhampton, United Kingdom
Start Date
July 1, 2026
Primary Completion Date
July 1, 2028
Completion Date
July 1, 2028
Last Updated
April 20, 2026
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06057402
NCT06383143
Lead Sponsor
The Royal Wolverhampton Hospitals NHS Trust
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions